Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

60.44 +0.73 (+1.22%)
Streaming Delayed Price Updated: 11:43 AM EDT, Mar 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,237,588
Open 60.13
Bid (Size) 60.44 (200)
Ask (Size) 60.46 (400)
Prev. Close 59.71
Today's Range 59.75 - 60.80
52wk Range 42.52 - 62.89
Shares Outstanding 2,222,113,553
Dividend Yield 4.17%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026
Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
1 ETF That Could Turn $100 Per Month Into $67,380 ↗
How does solid growth -- plus a 3.3% dividend yield sound? 
Via The Motley Fool
Topics ETFs Economy World Trade

Performance

YTD
+13.1%
+13.1%
1 Month
+0.1%
+0.1%
3 Month
+11.3%
+11.3%
6 Month
+30.4%
+30.4%
1 Year
+0.8%
+0.8%

More News

Read More
Bristol-Myers Squibb Co. (NYSE:BMY): A High-Yield Dividend Stock for Income Investors ↗
Via Chartmill
News headline image
1 S&P 500 Stock Worth Your Attention and 2 We Question
Via StockStory
Topics Stocks
News headline image
BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
Via MarketMinute
News headline image
3 Healthcare Stocks Paying the Highest Dividends of 2026 ↗
Via The Motley Fool
News headline image
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
News headline image
Why Bristol Myers Squibb Stock Crushed it in February ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
From Bristol Myers Squibb
Via Business Wire
News headline image
2 Top Healthcare Dividend Stocks to Buy and Hold Forever ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
News headline image
How to Spot Winning Innovation ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
FourWorld Takes a Major Swing on Sable Offshore (SOC), Buying 8 Million Shares ↗
Via The Motley Fool
Topics Energy Lawsuit
News headline image
Big Pharma Dividend Stock BMY Could Help Turn $100,000 Into a Seven‑Figure Retirement ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
Via MarketMinute
Topics Economy Intellectual Property
News headline image
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
From Bristol Myers Squibb
Via Business Wire
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
Via MarketMinute
Topics Intellectual Property
News headline image
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
Via FinancialNewsMedia
News headline image
3 Reasons to Avoid BMY and 1 Stock to Buy Instead
Via StockStory
Topics Stocks
News headline image
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO
Via MarketMinute
Topics Intellectual Property
News headline image
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
From Bristol Myers Squibb
Via Business Wire
News headline image
2 Large-Cap Stocks on Our Buy List and 1 That Underwhelm
Via StockStory

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 60.44
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 03/17/26 11:43 AM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 134.30B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 134B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS